Table 4.

Multivariate analysis among ΔCTs of genes and clinical variables

	Stage	Tumour size	Subtype	MI	LVI	Grade (FIGO)	Grade (nuclear)	Recurrence	Good outcome
	P-value	P-value	P-value	P-value	P-value	P-value	P-value	P-value	P-value
DAB2	0.77	0.51	0.61	0.11	0.25	0.65	0.65	0.7	0.58
Skil	0.03	0.92	0.83	0.41	0.24	1	1	0.88	0.99
Smad2	0.7	0.06	0.16	0.98	0.07	0.03	0.03	0.83	0.32
Smad3	0.33	0.24	0.15	0.19	0.52	0.02	0.02	0.34	0.45
Smad4	0.24	0.05	0.04	0.64	0.03	0	0	0.5	0.05
TGF-β1	0.84	0.65	0.97	0.15	0.22	0.12	0.12	0.47	0.04
TβRI	0.88	0.56	0.68	0.74	0.09	0.78	0.78	0.25	0.38
TβRII	0.36	0.43	0.09	0.33	0.05	0.81	0.81	0.15	0.35

CT, Cycle threshold; FIGO, International Federation of Gynecology and Obstetrics; LVI, lymphovascular invasion; MI, myometrial invasion; TβRI, transforming growth factor-β receptor type I; TβRII, transforming growth factor-β receptor type II; TGF, transforming growth factor.

P-values are for for testing of the association among mRNA levels of the eight genes and the clinical variables. Logistic regression was performed on the two groups, and the grouping that we considered for this analysis was similar to the one used in Table 2.